Ann Leen's most recent trade in Kalaris Therapeutics Inc. was a trade of 15,000 Common Stock done . Disclosure was reported to the exchange on Aug. 16, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 15,000 | 43,000 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 81,250 | 473,594 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 56,744 | 366,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 43,750 | 124,006 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 26,000 | 392,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 23,256 | 51,256 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 14,000 | 65,256 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 12 Nov 2021 | 14,266 | 2,294,876 | - | 22.3 | 317,628 | Common Stock |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 12 Nov 2021 | 6,122 | 2,288,254 | - | 21.9 | 134,167 | Common Stock |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.18 per share. | 12 Nov 2021 | 500 | 2,294,376 | - | 23.2 | 11,588 | Common Stock |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 12 Nov 2021 | 100 | 2,288,154 | - | 21.8 | 2,176 | Common Stock |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 10 May 2021 | 150,000 | 2,309,142 | - | 22.8 | 3,412,500 | Common Stock |
| Kalaris Therapeutics Inc | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 16 Mar 2021 | 3,025 | 2,459,142 | - | 30.0 | 90,751 | Common Stock |